[go: up one dir, main page]

WO2011156617A3 - Anti-egfr antibodies - Google Patents

Anti-egfr antibodies Download PDF

Info

Publication number
WO2011156617A3
WO2011156617A3 PCT/US2011/039821 US2011039821W WO2011156617A3 WO 2011156617 A3 WO2011156617 A3 WO 2011156617A3 US 2011039821 W US2011039821 W US 2011039821W WO 2011156617 A3 WO2011156617 A3 WO 2011156617A3
Authority
WO
WIPO (PCT)
Prior art keywords
egfr
egfr antibodies
antibodies
activation
egfrviii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/039821
Other languages
French (fr)
Other versions
WO2011156617A2 (en
Inventor
Fang Wang
Sylvie Vincent
William M. Winston, Jr.
Steve Botega
Donna Mcintosh
Ting Chen
Steven Tyler
Jeno Gyuris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aveo Pharmaceuticals Inc
Original Assignee
Aveo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc filed Critical Aveo Pharmaceuticals Inc
Publication of WO2011156617A2 publication Critical patent/WO2011156617A2/en
Publication of WO2011156617A3 publication Critical patent/WO2011156617A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member EGFRL858R/T790M are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of EGFRL858R/T790M, EGFRvIII or wild-type EGFR amplification.
PCT/US2011/039821 2010-06-09 2011-06-09 Anti-egfr antibodies Ceased WO2011156617A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35311810P 2010-06-09 2010-06-09
US61/353,118 2010-06-09

Publications (2)

Publication Number Publication Date
WO2011156617A2 WO2011156617A2 (en) 2011-12-15
WO2011156617A3 true WO2011156617A3 (en) 2012-03-01

Family

ID=44588165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/039821 Ceased WO2011156617A2 (en) 2010-06-09 2011-06-09 Anti-egfr antibodies

Country Status (1)

Country Link
WO (1) WO2011156617A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6441792B2 (en) 2012-05-17 2018-12-19 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Antigen binding protein that binds to EGFR
TW201843172A (en) * 2012-06-25 2018-12-16 美商再生元醫藥公司 anti-EGFR antibody and use thereof
WO2014028221A1 (en) 2012-07-31 2014-02-20 Crown Bioscience, Inc. Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug
CN102993305B (en) * 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 Humanized anti-human epidemic growth factor receptor (EGFR) antibody as well as encoding gene and application thereof
JP2017536347A (en) * 2014-10-17 2017-12-07 ノバルティス アーゲー Combination of ceritinib and EGFR inhibitor
CN106124775B (en) * 2016-06-30 2018-10-30 广州瑞博奥生物科技有限公司 Mouse antibodies hypotype fast typing kit and preparation method thereof
CN110612121A (en) 2017-05-11 2019-12-24 南克维斯特公司 Anti-EGFR/High Affinity NK Compositions and Methods for Chordoma Treatment
CN111116754A (en) * 2018-10-30 2020-05-08 天津亨佳生物科技发展有限公司 Specific TCR aiming at EGFR L858R gene mutation and application thereof
WO2023009529A2 (en) 2021-07-28 2023-02-02 Trustees Of Boston University Novel polypeptides and uses thereof
CN116333119B (en) * 2021-12-16 2024-02-23 徕特康(苏州)生物制药有限公司 anti-EGF receptor antibody, preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1612558A1 (en) * 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Method for detecting gluten
WO2008091701A2 (en) * 2007-01-25 2008-07-31 Dana-Farber Cancer Institute Use of anti-egfr antibodies in treatment of egfr mutant mediated disease

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CZ282603B6 (en) 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanized and chimeric monoclonal antibody, expression vector and pharmaceutical preparation
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
RU2335507C2 (en) 2001-06-13 2008-10-10 Генмаб А/С Human monoclonal antibodies to receptor of epidermal growth factor (egfr), method of their preparation and usage, hybridome, transfectome, transgene animal, expression vector
JP2005538706A (en) 2001-07-12 2005-12-22 ジェファーソン フーテ， Super humanized antibody
AU2002326531A1 (en) 2001-08-03 2003-02-17 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbb family members and methods of use thereof
AU2003215381A1 (en) 2002-02-25 2003-09-09 Georgetown University EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER
WO2003099205A2 (en) 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr
EP3037105B1 (en) 2003-06-27 2021-03-17 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1612558A1 (en) * 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Method for detecting gluten
WO2008091701A2 (en) * 2007-01-25 2008-07-31 Dana-Farber Cancer Institute Use of anti-egfr antibodies in treatment of egfr mutant mediated disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PEREZ-TORRES MARIANELA ET AL: "Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations", THE JOURNAL OF BIOLOGICAL CHEMISTRY 29 DEC 2006,, vol. 281, no. 52, 29 December 2006 (2006-12-29), pages 40183 - 40192, XP002576289 *

Also Published As

Publication number Publication date
WO2011156617A2 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
WO2011156617A3 (en) Anti-egfr antibodies
WO2011136911A3 (en) Anti-erbb3 antibodies
PH12012502215A1 (en) Anti-fgfr2 antibodies
WO2013006547A3 (en) Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2012058592A3 (en) Non-antagonistic egfr-binding molecules and immunoconjugates thereof
WO2012058588A3 (en) Novel egfr-binding molecules and immunoconjugates thereof
WO2015038984A3 (en) Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2010002862A3 (en) Fibroblast growth factor receptor 3 (fgfr3) binding proteins
PH12018501473A1 (en) Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
PH12014502437A1 (en) Anti-egfr antibodies and uses threof
PH12016501109A1 (en) Novel anti-dpep3 antibodies and methods of use
PH12014502641B1 (en) Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2012033987A3 (en) Anti-human folate receptor beta antibodies and methods of use
MX2016005763A (en) Novel anti-claudin antibodies and methods of use.
WO2013119960A3 (en) Anti-cd324 monoclonal antibodies and uses thereof
SG10201808837RA (en) Anti-egfr antibodies and antibody drug conjugates
MX2019009654A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof.
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
WO2015050959A8 (en) Anti-kit antibodies and methods of use thereof
HK1216850A1 (en) Anti-ntb-a antibodies and related compositions and methods
MX2014001766A (en) Neuregulin antibodies and uses thereof.
HK1179516A (en) Anti-fgfr2 antibodies
HK1230276A1 (en) Novel anti-dpep3 antibodies and methods of use
HK1228290A1 (en) Novel anti-claudin antibodies and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11731582

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11731582

Country of ref document: EP

Kind code of ref document: A2